asco23 - lba3: os analysis from the adaura trial of adjuvant osimertinib in resected egfr‐mutate...
Published 1 year ago • 705 plays • Length 11:37Download video MP4
Download video MP3
Similar videos
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
3:19
adjuvant osimertinib in resected egfr-mutated nsclc
-
11:58
asco 2023 - astrazeneca - positive results from adaura phase iii trial
-
47:21
asco 2023: highlights and analysis
-
0:55
lung cancer at asco 2023: adaura and adcs
-
6:33
asco daily news 2023 plenary update - lba3: adaura
-
1:42
adaura: the benefit of adjuvant osimertinib
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
5:54
key points from the adaura trial: osimertinib - targeted therapies in lung cancer 2023
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
0:20
lung cancer trial updates at asco 2023
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
31:14
adaura, keynote-671, and other key advances in lung cancer at asco23
-
4:24
reflections on the adaura study